Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Recruiting, Not yet recruiting Studies | NCT02649829
Previous Study | Return to List | Next Study

Autologous Dendritic Cell Vaccination in Mesothelioma (MESODEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02649829
Recruitment Status : Recruiting
First Posted : January 8, 2016
Last Update Posted : December 11, 2019
Sponsor:
Collaborators:
Kom Op Tegen Kanker
stichting tegen kanker
Information provided by (Responsible Party):
Zwi Berneman, University Hospital, Antwerp

Brief Summary:
In this multicenter phase I/II trial, dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be used in conjunction with conventional chemotherapy for the frontline treatment of malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with WT1-targeted DC vaccination is feasible and safe and enables the induction of both systemic and in situ mesothelioma-specific immune responses in patients with MPM.

Condition or disease Intervention/treatment Phase
Malignant Pleural Mesothelioma Biological: dendritic cell vaccination plus chemotherapy Phase 1 Phase 2

Detailed Description:

Malignant pleural mesothelioma (MPM) is a highly aggressive and in virtually all cases fatal cancer that is tightly associated with prior asbestos exposure. Despite some improvement over time, the prognosis of patient diagnosed with MPM remains dismal with a median overall survival from diagnosis of only 12 months.

In this single arm phase I/II trial the investigators want to demonstrate the feasibility and safety of WT1-targeted dendritic cell vaccination in MPM patients as frontline treatment in conjunction with first line platinum/pemetrexed-based chemotherapy and the induction of both systemic and in situ mesothelioma-specific immune responses. During three years of recruitment the investigators aim at including 20 patients diagnosed with histologically proven epithelial MPM (WHO grade 0-1) who are able to undergo leukapheresis, chemotherapy, immunotherapy and pleurectomy/decortication (P/D; in case of resectable disease). Patients who underwent prior treatment for MPM or with a history of another malignancy within the last five years will be excluded.

The intention of this study is to administer four vaccine doses in combination with standard of care of four 3-weekly cytoreductive platinum/pemetrexed-based chemotherapy cycles to each participant and prior to surgery (P/D) in the case of resectable MPM. Patients will receive four 3-weekly intradermal vaccinations with autologous WT1 messenger (m)RNA-loaded dendritic cells (V1-4), at day 14 after the start of each chemotherapy cycle (CT1-4).

The dendritic cell therapy product will be generated and administered in the Antwerp University Hospital, more specifically the Center for Cell Therapy and Regenerative Medicine (CCRG) and the Division of Hematology, both headed by Prof. Zwi Berneman.

The DC vaccines will be under embargo from release until the safety and quality control test results have become available and all release criteria have been met. A detailed overview of all applicable release criteria is provided in the investigational medicinal product dossier. The embargo period generally lasts 3 weeks counting from the day of cryopreservation (i.e. 8 days after leukapheresis).

Recruitment started in August 2017. Study-related follow-up of the included patients is intended to be until 90 days after final DC vaccine administration or 22 months after diagnosis, whichever occurs later. In addition to feasibility and safety of the chemoimmunotherapy schedule, the investigators will look for the time to progression (TTP), progression-free survival (PFS), overall survival (OS), systemic immunogenicity and local immunogenicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma
Actual Study Start Date : August 1, 2017
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Single Arm
dendritic cell vaccination plus chemotherapy
Biological: dendritic cell vaccination plus chemotherapy

A. Chemoimmunotherapy:

  1. four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.
  2. four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.

B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle.

Other Name: chemoimmunotherapy




Primary Outcome Measures :
  1. Number of MPM patients with feasible and safe DC vaccine production [ Time Frame: Vaccine production and quality testing (i.e. 4 weeks after leukapheresis) ]

    Production of autologous DC vaccines from newly diagnosed MPM patients will be evaluated for:

    1. Feasibility, assessed by success of leukapheresis and production of sufficient (i.e. at least 4 vaccines) and qualified (phenotypic and functional requirements) vaccines.
    2. Safety, assessed by microbiological testing (bacteria, yeast, fungi, mycoplasma, endotoxin) of the DC vaccines.

  2. Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame [ Time Frame: After the chemoimmunotherapy treatment (+/- 15 weeks after entry to trial) ]

    Administration of 4 autologous DC vaccines combined with four 3-weekly platinum/pemetrexed-based chemotherapy cycles will be evaluated for:

    1. Feasibility, assessed by successful administration of DC vaccines and prior to surgery in case of resectable disease.
    2. Safety, assessed by local (e.g. skin reactions at injection site) and systemic (toxicity grading according to the latest version of the CTCAE and CTC ) tolerability to the treatment.


Secondary Outcome Measures :
  1. Objective clinical responses by tumor evaluation (clinical efficacy) [ Time Frame: Through study completion, at least after 4 DC vaccinations, prior to surgery (in case of resectable disease) + three months after the last intervention and within every 12 months during follow-up ]

    Objective clinical responses to the chemoimmunotherapy and, in case of resectable disease, after surgery as compared to baseline tumor evaluation prior to treatment (i.e. at diagnosis), will be evaluated with:

    1. radiographic assessments (CT imaging) of the tumor response using the modified RECIST criteria.
    2. FDG-PET assessments of the tumor response using the PERCIST criteria.

    Patients will be followed for disease progression; time to progression (TTP) and progression-free survival (PFS).


  2. Overall survival (clinical efficacy) [ Time Frame: Through study completion, an average of 1 year ]
    Patients will be followed for survival, from diagnosis and from start of treatment, for which the accurate date and reason of death (cancer-related or non-related) will be recorded for every patient.

  3. Systemic immunogenicity [ Time Frame: After the fourth DC vaccine (i.e. post chemoimmunotherapy, prior to surgery in case of resectable disease) ]

    Systemic immunogenicity will be evaluated by:

    1. Detection of WT1-specific T cell immunity and innate immunity in peripheral blood.
    2. Response to delayed-type hypersensitivity (DTH) skin testing to the DC vaccine.

  4. Local immunogenicity [ Time Frame: Upon surgery (P/D) ]
    Local immunogenicity will be evaluated by detection of immune profile in tumor biopsies and/or pleurectomy specimens (in case of resectable disease).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis with histologically proven epithelial
  • Aged ≥ 18 years at the time of enrollment
  • WHO performance status 0-1 at the time of enrollment
  • Fit to undergo general anesthesia, a thoracoscopy, leukapheresis, chemotherapy, immunotherapy and P/D (in case of resectable disease)
  • No history of receiving any investigational treatment within 28 days of study enrollment
  • No history of intolerance to pemetrexed and/or cisplatin
  • Women of child bearing potential must have negative serum or urine pregnancy test at the time of screening. They should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least hundred days after the last study treatment. If pregnancy does occur within this time period, the Principal investigator must be informed as soon as possible. Female subjects who are breastfeeding should discontinue nursing prior to the first dose of study treatment and until hundred days after the last study treatment
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discusses with the patient before registration in the trial. Absence of any other inability or unwillingness to comply with the requirements of the protocol as assessed by the investigator
  • Before patient registration written informed consent must be given according to ICH/GCP, and national/local regulations

Exclusion Criteria:

  • Unwilling or unable to comply with the study requirements
  • Prior treatment for MPM
  • History of another malignancy within the last five years (except for carcinoma in situ of the cervix, basal cell or spinocellular carcinoma of the skin or unless the investigator rationalizes otherwise)
  • Known proven metastases
  • Known concomitant presence of any immunosuppressive disease (e.g. HIV) or any active autoimmune condition, except for vitiligo
  • Pregnant or breast-feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02649829


Contacts
Layout table for location contacts
Contact: Zwi N Berneman, MD, PhD 0032 3 821 39 15 zwi.berneman@uza.be
Contact: Eva Lion, MSc, PhD +3238214112 eva.lion@uantwerpen.be

Locations
Layout table for location information
Belgium
Antwerp University Hospital Recruiting
Edegem, Antwerp, Belgium, 2650
Contact: Zwi N Berneman, MD, PhD       zwi.berneman@uza.be   
Contact: Sébastien Anguille, MD, PhD       sebastien.anguille@uza.be   
Sub-Investigator: Paul Germonpré, MD         
Sub-Investigator: Koen Deschepper, MD         
AZ Middelares Recruiting
Ghent, Belgium, 9000
Contact: Local investigator: Paul Germonpré, MD, PhD         
AZ Nikolaas Recruiting
Sint-Niklaas, Belgium, 9100
Contact: Local investigator: Koen Deschepper, MD         
Sponsors and Collaborators
University Hospital, Antwerp
Kom Op Tegen Kanker
stichting tegen kanker
Investigators
Layout table for investigator information
Study Director: Zwi N Berneman, MD, PhD Antwerp University Hospital, Division of Hematology and Center for Cell Therapy and Regenerative Medicine
Principal Investigator: Eva Lion, MSc, PhD University of Antwerp, Laboratory of Experimental Hematology
Principal Investigator: Evelien LJ Smits, MSc, PhD University of Antwerp, Laboratory of Experimental Hematology
Principal Investigator: Sébastien Anguille, MD, PhD Antwerp University Hospital, Division of Hematology
Publications:
Berneman ZN, Van de Velde AL, Willemen Y, Anguille S, Saevels K, Germonpré P, Huizing MT, Peeters M, Snoeckx A, Parizel P, Van Tendeloo VF, Lion E, Nijs G, Stein B, Vermeulen K, Maes MB, Malfait R, Vrelust I, Verlinden A, Gadisseur AP, Schroyens WA, Lammens M and Smits EL. Blood 124(21): 310-310, 2014.
Berneman Z, Germonpre P, Huizing MT, Van De Velde A, Nijs G, Stein B, Van Tendeloo V, Lion E, Smits EL and Anguille S. J Clin Oncol 32:5s(suppl): abstr 7583, 2014.
Willemen Y, Huizing MT, Smits E, Anguille S, Nijs G, Stein B, Van Tendeloo V, Peeters M, Berneman Z. J Clin Oncol 30(suppl): abstr e13051, 2012.
Z. Berneman, A. Van de Velde, S. Anguille, Y. Willemen, M. Huizing, P. Germonpré, K. Saevels, G. Nijs, N. Cools, A. Van Driessche, B. Stein, H. De Reu, W. Schroyens, A. Gadisseur, A. Verlinden, K. Vermeulen, M. Maes, M. Lammens, H. Goossens, M. Peeters, V. Van Tendeloo, E. Smits. Vaccination with Wilms' Tumor Antigen (WT1) mRNA-Electroporated Dendritic Cells as an Adjuvant Treatment in 60 Cancer Patients: Report of Clinical Effects and Increased Survival in Acute Myeloid Leukemia, Metastatic Breast Cancer, Glioblastoma and Mesothelioma. Cytotherapy 2016, 18(6), p. S13-14
Z. Berneman, S. Anguille, Y. Willemen, A. Van de Velde, P. Germonpré, M. Huizing, V. Van Tendeloo, K. Saevels, L. Rutsaert, K. Vermeulen, A. Snoeckx, B. Op de Beeck, N. Cools, G. Nijs, B. Stein, E. Lion, A. van Driessche, M. Peeters, E. Smits. Vaccination of cancer patients with dendritic cells electroporated with mRNA encoding the Wilms' Tumor protein (WT1): correlation of clinical effect and overall survival with T-cell response. Cytotherapy 2019, 21(5), p. S10.

Layout table for additonal information
Responsible Party: Zwi Berneman, Study coordinator, University Hospital, Antwerp
ClinicalTrials.gov Identifier: NCT02649829    
Other Study ID Numbers: CCRG13-002
First Posted: January 8, 2016    Key Record Dates
Last Update Posted: December 11, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zwi Berneman, University Hospital, Antwerp:
dendritic cell vaccination
chemo-immunotherapy
Wilms' tumor 1 (WT1)
Additional relevant MeSH terms:
Layout table for MeSH terms
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial
Vaccines
Immunologic Factors
Physiological Effects of Drugs